Inhibition with selective antagonist ML-193, as well as GPR55 absence (in GPR55ko), improved Bederson’s neurological scores by 60% (at day 1 after stroke, not shown) and improved survival rates post-tMCAO (Figure 1A). This evidence concerns the gene GPR55 and stroke disorder.